Purpose: The aim of this study was to perform an objective and subjective evaluation of the efficacy of positioning stents in radiation-induced xerostomia in patients with tongue carcinoma. Materials and Methods: A total of 30 patients with tongue carcinoma and undergoing conventional radiotherapy were randomly assigned to control (n = 15) and study (n = 15) groups, without and with a positioning stent, respectively. Assessment of salivary output reduction was done before and after radiotherapy, at 3-and 6-month intervals, by measurement of unstimulated and stimulated salivary flow rates (objective evaluation). Xerostomia (subjective evaluation) was noted using six items from the Quality of Life Head and Neck Module (QLQ-H&N35) as proposed by the European Organization for Research and Treatment of Cancer. The significance level was set at .05. Results: Mean unstimulated and stimulated salivary flow rates at 3-and 6-month intervals revealed significantly (P < .05) higher scores for the study group as compared with the control group. The mean quality of life scores in the study group were significantly (P < .05) lower compared with the control group. Conclusion: The use of a positioning stent minimized radiation-induced xerostomia and its symptoms. Int J Prosthodont 2016;29:455-460.
O ral cancer is the most common cancer in India, with the highest mortality rate. 1 It is related to frequent use of betel quid, which consists of tobacco, areca nut, catechu, and lime. Management/ treatment includes radiotherapy despite associated complications such as radiation-induced xerostomia. Xerostomia is the subjective feeling of oral dryness and occurs with a 45% to 50% reduction in saliva flow. Under normal conditions, 80% to 85% of saliva is produced by major salivary glands and can be serous, mucus, or mixed in nature. Saliva is essential for digestion, lubrication, and tissue protection. Serous secretion is mainly released by the parotid gland, and serous acini are more sensitive to radiation doses (> 45 Gy) than mucous acini. The latter are mainly present in the submandibular gland. In most cases of tongue carcinoma, radiation treatment doses exceed 65 Gy and result in xerostomia that is cited as a major cause of compromised quality of life (QoL) for patients.
Various prosthetic devices, such as tissue bolus devices, shielding stents, and positioning stents, are used to facilitate the delivery of radiation. Positioning stents are used to move the parotid and submandibular salivary gland away from the radiation field for effective administration of radiotherapy. Stents can reduce the chances of xerostomia, which is objectively defined as salivary gland hypofunction or hyposalivation. 2 Patients report symptoms such as a burning sensation or difficulty in swallowing as a consequence of mucositis. Published literature confirms the reduction in saliva production (hyposalivation) after radiation, 3 and a few studies have shown the (subjective only) effectiveness of radiation stents in minimizing the adverse effects of radiation. 3, 4 Patient reporting bias can be easily introduced in a subjective assessment; consequently, this study attempted to objectively and subjectively evaluate the effectiveness of positioning stents in radiation-induced xerostomia in tongue carcinoma patients.
Materials and Methods
The study was conducted between January 2011 and June 2012 in a tertiary care hospital. Of 38 patients assessed for eligibility, 30 were recruited.
Inclusion criteria were as follows:
• Carcinoma of the posterior tongue • Exposed to same radiation field: radiation stent, radiation source, and dosages between 60 and 70 Gy • Mouth opening of at least 15 mm (interincisal) • Able to provide salivary samples • Dental condition enabling adequate stent retention 5 Exclusion criteria were as follows:
• Local extension of the tongue that may interfere with appliance fabrication or cause trauma • Intraoral infection or systemic disease • Neck dissections or resection of salivary gland Necessary ethical clearance was obtained from the institutional ethics committee and written informed consent was obtained from participants. The participants were randomly assigned to two groups of equal numbers (control group without stent and study group with stent) using a computer-generated block scheme by one of the authors (B.P.S.). Participants were given a sealed envelope and were sent to another author (P.M.) for fabrication of the positioning stent or as a control (no stent). QoL and salivary flow measurement before radiotherapy and during follow-up were recorded by an investigator (P.C.) who was blinded to the objective of the study. During radiotherapy, repeatable position was maintained through teeth in occlusion in the control (n = 15) or by positioning stent in the study group (n = 15). Figure 1 shows participant distribution throughout the study.
A standardized technique was followed wherein the positioning stent was fabricated at one-half to two-thirds of maximum mouth opening through inter occlusal records. Articulation was done at this position and a block of modeling wax with occlusal index was interposed on both sides between the maxillary and mandibular casts. Double-thickness baseplate wax was applied to the inferior aspect of these blocks extending lingually from the lower occlusal table horizontally so that it could depress the tongue within the lingual borders of the body of the mandible and thus shift the parotid and submandibular gland away from the simulation zone of radiation. 7 A hole was made in the anterior horizontal segment, and patients were instructed to maintain the tip of the tongue in this orientation hole during treatment to ensure consistent, reproducible tongue position ( Fig  2) . The appliance was then processed with heat-polymerizing acrylic resin (Trevalon, Dentsply), finished, polished, and inserted. The participants were instructed to wear the appliance at the time of radiotherapy, and a simulation radiograph was taken (Fig 3) . All participants were treated with conventional radiotherapy technique with a dose of 70 Gy in two phases. The first phase, with a 46-Gy dose, was divided into 23 fractions at the rate of 200 cGy per fraction (5 fractions per week) targeting the primary lesion and the whole neck by parallel opposite field. The second phase, with a 24-Gy dose, was divided into 12 fractions, sparing the spinal cord. This phase was administered with concurrent weekly cisplatin at 35 mg/m 2 (capped at 50 mg) with standard hydration and antiemetic cover. The efficiency of the stent was objectively evaluated by measuring the reduction in unstimulated and stimulated salivary flow (milliliters per minute) before radiotherapy and after radiotherapy at 3 and 6 months. Unstimulated saliva was measured by asking participants to allow saliva to accumulate in the floor of the mouth for 60 seconds without swallowing. Participants were instructed to then spit the accumulated saliva into a preweighed 50-ml vial. The participants were asked to repeat this procedure four more times for a total collection time of 5 minutes. Participants were instructed not to swallow any saliva for the entire 5-minute collection procedure. After collection, fresh lemon juice was applied with cottontipped applicators to the lateral tongue bilaterally five times over a 2-minute period (at 0, 30, 60, 90, and 120 seconds). The mouth was then emptied of the retained lemon juice solution. Saliva was then collected for 5 minutes in the same manner as for unstimulated saliva. The saliva was weighed on a precision balance, and saliva flow was calculated assuming 1 mg saliva was equal to 1 mL saliva. 8 The efficiency of the positioning stent was assessed subjectively by completing a module and symptoms scale (six items) related to xerostomia in the European Organization for Research and Treatment Quality of Life Head and Neck Module (QLQ-H&N35). 9 All items were rated on a four-point Likert scale on which higher scores represent a greater degree of adverse symptoms, and the scores were averaged. The reliability and validity of these questionnaires have been confirmed in a number of international studies. 9 In the present study, this questionnaire was completed by the participants before radiotherapy and after radiotherapy at 3 and 6 months.
Data was analyzed using SPSS version 16.0 (IBM). QoL data was ordinal in nature and hence was compared using nonparametric tests. Data for salivary flow rate was assessed for normality and was found to be symmetric and normal; hence, a parametric analysis plan was adopted. For between-group comparisons, Mann-Whitney U test and Student t test were used. Change in QoL was studied using Wilcoxon signed rank test. Correlation between salivary flow rate and QoL scores was assessed using Spearman rank correlation. The confidence level of the study was kept at 95%, hence P < .05 indicated a statistically significant difference. 
Results
The unstimulated (at 3-[P = .044] and 6-month [P = .023] intervals) and stimulated salivary flow rates (at 3-[P = .021] and 6-month [P = .020] intervals) revealed significantly higher scores for the study group compared to the control group (Table 1) . The mean QoL scores in the study group were significantly lower compared with the control group, both at 3 (P < .001) and 6 months (P < .001) ( Table 2 ). The changes in the mean QoL scores in both groups were significantly higher between baseline and 3 months (P = .002 for both groups) compared with that between 3 and 6 months (P = .003 for the control group; P = .002 for the study group) (Tables 3 and 4) . Correlation between QoL scores and unstimulated salivary flow were random in nature (inverse before radiotherapy, direct at 3 months, and inverse at 6 months), and statistically nonsignificant. However, for stimulated salivary flow, before radiotherapy the correlation was direct in nature (positive sign), and statistically nonsignificant (P > .05). At 3 and 6 months, it was inverse in nature (negative sign), and statistically nonsignificant.
Discussion
A significant decrease was found in unstimulated and stimulated salivary flow rates, along with fewer symptoms in participants randomized with positioning stents. This decrease in salivary flow rate could be the result of exclusion of the superior aspect of the parotid from the radiation field via the bite blocks in the positioning stent increasing the mouth opening and thus the parotids. The minor salivary glands, which significantly contribute to serous production, were also out of the radiation field. The results also showed that the percentage decrease in salivary flow rate was slow in the study group as compared with the control, possibly for the same reason. Parotid flow rate diminished immediately after radiotherapy with a maximal deterioration within 1 to 3 months compared with baseline, which was around 63.33% of normal for the control group and 57.33% of normal for the study group. The parotid salivary glands contribute 60% to 65% of the total salivary output, largely contribute to stimulated salivary flow, and are extremely sensitive to radiotherapy. This reduction in salivary flow and subsequent recovery depends on the dose and the proportion of the gland included in the treatment volume. The present findings of significantly higher unstimulated and stimulated salivary flow rates in the study group after the use of positioning stents replicates the findings of Goel et al. 10 In the present study, the authors chose to estimate saliva production by stimulating it with fresh lemon juice, which is readily available. Sialometry is the most objective method to assess salivary function and to determine the quantity of resting and stimulated whole saliva. 8, 9 The statistically nonsignificant correlation between salivary flow rates and QoL can be attributed to the small sample size. This may also be because the focus was on changes in time and not on relations at fixed time points. Similar to the present result. Parliament et al reported an inverse correlation between unstimulated and stimulated whole salivary flow and xerostomia-specific items at 1 month, which had disappeared at 3 months and 12 months after treatment. 11 In contrast with previous findings, 10 the device helped control the trismus that is a common side effect of radiation. It also helped in consistently placing the tongue lesion in the same position at every radiotherapy session, making the treatment more effective. Although the literature is replete with reports showing encouraging results in terms of effective parotid sparing (at least of the contralateral gland) with intensity-modulated radiotherapy (IMRT), 12 in resource-constrained environments such as India, where conventional radiotherapy continues to take center stage in the locally advanced head and neck, positioning stent use could be a cost-effective alternative. Because of its high cost, IMRT is not an option for all patients. Small sample size and short follow-up period were the main limitations of the present study. Unstimulated r = -.046; P = .832 r = .187; P = .381 r = -.212; P = .320 Stimulated r = .137; P = .523 r = -.328; P = .117 r = -.386; P = .062
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Minimal recovery of the salivary glands at 1 year has been reported in the literature, but future research is needed with a large cohort and longer follow-up. Incomplete improvement in xerostomia also emphasizes the need to enhance protection of the submandibular glands, the greatest contributors to whole saliva during rest. Treatment focus should be on optimized/new approaches to further reduce the dose to the parotids, and particularly the submandibular and minor salivary glands, as these glands are major contributors to moistening of oral tissues. Further diagnostic tools, such as conventional sialography and salivary scintigraphy of salivary glands, which allows better visualization of deeply situated tissues such as the deep lobe of the parotid gland, can be used in future studies to more accurately assess the role of positioning stents in reducing radiation-induced xerostomia.
Conclusions
A custom intraoral positioning stent indexed to the dentition to inferiorly position the tongue appears to maintain unstimulated and stimulated saliva flow in patients irradiated for inoperable tongue cancer, when compared with patients irradiated without a custom positioning stent.
